DMOG treatment increased the ratio of CXCR4-EGFP+ CD11b+/CD206+ to CD11b+/CD86+ cells by 2.6-fold, suggesting an improved fine-tuning of reparative M2-like CD206+ compared to inflammatory CD86+ cells in the ischemic heart associated with (3) reduced apoptotic cell death, increased neovascularization, reduced scar size, and (4) an improved heart function after MI (Fig. 7). This evidence concerns the gene CXCR4 and myocardial infarction.